<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK25565" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK25565/" /><meta name="ncbi_pagename" content="Congenital Cataracts, Facial Dysmorphism, and Neuropathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Congenital Cataracts, Facial Dysmorphism, and Neuropathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Congenital Cataracts, Facial Dysmorphism, and Neuropathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/04/06" /><meta name="citation_author" content="Luba Kalaydjieva" /><meta name="citation_author" content="Teodora Chamova" /><meta name="citation_pmid" content="20301787" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK25565/" /><meta name="citation_keywords" content="CCFDN" /><meta name="citation_keywords" content="CCFDN" /><meta name="citation_keywords" content="RNA polymerase II subunit A C-terminal domain phosphatase" /><meta name="citation_keywords" content="CTDP1" /><meta name="citation_keywords" content="Congenital Cataracts, Facial Dysmorphism, and Neuropathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Congenital Cataracts, Facial Dysmorphism, and Neuropathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Luba Kalaydjieva" /><meta name="DC.Contributor" content="Teodora Chamova" /><meta name="DC.Date" content="2017/04/06" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK25565/" /><meta name="description" content="Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) is characterized by abnormalities of the eye (bilateral congenital cataracts, microcornea, microphthalmia, micropupils); mildly dysmorphic facial features apparent in late childhood; and a hypo/demyelinating, symmetric, distal peripheral neuropathy. The neuropathy is predominantly motor at the onset and results in delays in early motor development, progressing to severe disability by the third decade. Secondary scoliosis and foot deformities are common. Sensory neuropathy develops after age ten years. Most affected individuals have a mild non-progressive intellectual deficit and cerebellar involvement including ataxia, nystagmus, intention tremor, and dysmetria. All have short stature and subnormal weight. Adults have hypogonadotropic hypogonadism. Parainfectious rhabdomyolysis (profound muscle weakness, myoglobinuria, and excessively elevated serum concentration of creatine kinase usually following a viral infection) is a potentially life-threatening complication. To date all affected individuals and carriers identified have been from the Roma/Gypsy population." /><meta name="og:title" content="Congenital Cataracts, Facial Dysmorphism, and Neuropathy" /><meta name="og:type" content="book" /><meta name="og:description" content="Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) is characterized by abnormalities of the eye (bilateral congenital cataracts, microcornea, microphthalmia, micropupils); mildly dysmorphic facial features apparent in late childhood; and a hypo/demyelinating, symmetric, distal peripheral neuropathy. The neuropathy is predominantly motor at the onset and results in delays in early motor development, progressing to severe disability by the third decade. Secondary scoliosis and foot deformities are common. Sensory neuropathy develops after age ten years. Most affected individuals have a mild non-progressive intellectual deficit and cerebellar involvement including ataxia, nystagmus, intention tremor, and dysmetria. All have short stature and subnormal weight. Adults have hypogonadotropic hypogonadism. Parainfectious rhabdomyolysis (profound muscle weakness, myoglobinuria, and excessively elevated serum concentration of creatine kinase usually following a viral infection) is a potentially life-threatening complication. To date all affected individuals and carriers identified have been from the Roma/Gypsy population." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK25565/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ccfdn/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK25565/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE895F0AE04241F10000000002AA012B.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK25565_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK25565_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pai-1-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ondine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK25565_"><span class="title" itemprop="name">Congenital Cataracts, Facial Dysmorphism, and Neuropathy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: CCFDN</div><p class="contrib-group"><span itemprop="author">Luba Kalaydjieva</span>, MD, PhD and <span itemprop="author">Teodora Chamova</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK25565_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK25565_ai__"><div class="contrib half_rhythm"><span itemprop="author">Luba Kalaydjieva</span>, MD, PhD<div class="affiliation small">Laboratory for Molecular Genetics<br />Harry Perkins Institute of Medical Research and Centre for Medical Research<br />The University of Western Australia<br />Perth, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.ude.awu@aveijdyalak.abul" class="oemail">ua.ude.awu@aveijdyalak.abul</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Teodora Chamova</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />University Hospital Alexandrovska<br />Medical University of Sofia<br />Sofia, Bulgaria<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gb.vba@hctarodoet" class="oemail">gb.vba@hctarodoet</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 2, 2010</span>; Last Update: <span itemprop="dateModified">April 6, 2017</span>.</p><p><em>Estimated reading time: 19 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ccfdn.Summary" itemprop="description"><h2 id="_ccfdn_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) is characterized by abnormalities of the eye (bilateral <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> cataracts, microcornea, microphthalmia, micropupils); mildly <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> facial features apparent in late childhood; and a hypo/demyelinating, symmetric, distal peripheral neuropathy. The neuropathy is predominantly motor at the onset and results in delays in early motor development, progressing to severe disability by the third decade. Secondary scoliosis and foot deformities are common. Sensory neuropathy develops after age ten years. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a mild non-progressive intellectual deficit and cerebellar involvement including ataxia, nystagmus, intention tremor, and dysmetria. All have short stature and subnormal weight. Adults have hypogonadotropic hypogonadism. Parainfectious rhabdomyolysis (profound muscle weakness, myoglobinuria, and excessively elevated serum concentration of creatine kinase usually following a viral infection) is a potentially life-threatening complication. To date all affected individuals and carriers identified have been from the Roma/Gypsy population.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CCFDN is based on clinical findings. <i>CTDP1</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause CCFDN. Targeted analysis identifies the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> IVS6+389C&#x0003e;T in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 6, the <i>CTDP1</i> <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in the Roma/Gypsy population.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Cataracts are treated surgically; exaggerated inflammatory response and foreign-body reaction to contact lenses and intraocular lenses warrant close postoperative follow up. Peripheral neuropathy is managed symptomatically in the usual manner. Secondary spine and foot deformities may require surgical intervention. Hormone replacement therapy for hypogonadotropic hypogonadism may help prevent osteoporosis.</p><p><i>Prevention of secondary complications:</i> Close monitoring during and after anesthesia for potentially life-threatening complications (pulmonary edema, inspiratory stridor, malignant hyperthermia, and epileptic seizures). Awareness of rhabdomyolysis as a potential complication following viral infections in order to seek medical attention with the first recognizable symptoms and to provide oral corticosteroid treatment (for 2-3 weeks for optimal recovery).</p><p><i>Surveillance:</i> Annual examinations for possible ophthalmologic, neurologic, and endocrine manifestations.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate the older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to identify as early as possible those who would benefit from early initiation of treatment and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CCFDN is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. If the pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk family members, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="ccfdn.Diagnosis"><h2 id="_ccfdn_Diagnosis_">Diagnosis</h2><div id="ccfdn.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) <b>should be suspected</b> in individuals with the following clinical findings:</p><ul><li class="half_rhythm"><div>Bilateral <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> cataracts, microcornea, and micropupils</div></li><li class="half_rhythm"><div>Mildly <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> facial features apparent from late childhood</div></li><li class="half_rhythm"><div>Hypo/demyelinating peripheral neuropathy</div></li><li class="half_rhythm"><div>Mild non-progressive intellectual deficit</div></li><li class="half_rhythm"><div>Intrauterine growth retardation with subsequent small stature and subnormal weight in adulthood</div></li></ul></div><div id="ccfdn.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CCFDN <b>is established in</b> a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CTDP1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK25565/table/ccfdn.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="figccfdnTmoleculargenetictestingusedi" rid-ob="figobccfdnTmoleculargenetictestingusedi">Table 1</a>). Molecular genetic testing approaches can include <b>targeted analysis of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></b> and <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>:</p><ul><li class="half_rhythm"><div><b>Targeted analysis of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>,</b>
<a class="figpopup" href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figccfdnTselectedctdp1pathogenicvarian" rid-ob="figobccfdnTselectedctdp1pathogenicvarian">c.863+389C&#x0003e;T</a> (also known as IVS6+389C&#x0003e;T) in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 6 (a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in the Roma/Gypsy population) can be performed first in individuals of Roma/Gypsy ancestry. To date, all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and carriers identified have been from the Roma/Gypsy population.</div></li><li class="half_rhythm"><div><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Although it is theoretically possible for other sequence variants in <i>CTDP1</i> to cause CCFDN, no variants other than c.863+389C&#x0003e;T have been reported to date.</div></li></ul><p>It is important to note that c.863+389C&#x0003e;T reduces, but does not abolish, <i>CTDP1</i> expression (see <a href="#ccfdn.Molecular_Genetics">Molecular Genetics</a>). It is not known if complete loss of <i>CTDP1</i> results in different clinical features or is compatible with life.</p><div id="ccfdn.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Congenital Cataracts, Facial Dysmorphism, and Neuropathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25565/table/ccfdn.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccfdn.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CTDP1</i></td><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis</td><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Detects <a class="figpopup" href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figccfdnTselectedctdp1pathogenicvarian" rid-ob="figobccfdnTselectedctdp1pathogenicvarian">c.863+389C&#x0003e;T</a>, the <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in the Roma/Gypsy population</td></tr><tr><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">The Roma/Gypsy <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>, c.863+389C&#x0003e;T, is the only <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> described to date.</td></tr><tr><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_ccfdn.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ccfdn.TF.1.1"><p class="no_margin">See <a href="/books/NBK25565/#ccfdn.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ccfdn.TF.1.2"><p class="no_margin">See <a href="#ccfdn.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ccfdn.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ccfdn.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="ccfdn.TF.1.5"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="ccfdn.Clinical_Characteristics"><h2 id="_ccfdn_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ccfdn.Clinical_Description"><h3>Clinical Description</h3><p>Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) is a complex disorder whose major manifestations involve the anterior segment of the eye, the skull and face, the nervous system, and the endocrine system [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.1999b.165">Tournev et al 1999b</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>, <a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>, <a class="bk_pop" href="#ccfdn.REF.lassuthova.2014.46">Lassuthova et al 2014</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</p><div id="ccfdn.Eye"><h4>Eye</h4><p>Congenital cataracts are the invariable first manifestation of the disease [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>]. The cataracts are bilateral and can appear as anterior or posterior subcapsular opacities with clouding of the adjacent part of the lens nucleus or as total cataracts involving the entire lens [<a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>].</p><p>Other ocular manifestations include microcornea, microphthalmia (documented by axial length measurements), and micropupils with fibrotic margins, showing sluggish constriction to light and dilation to mydriatics [<a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>].</p><p>Horizontal pendular nystagmus is very common [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>, <a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>] and unrelated to the visual defect caused by the cataracts.</p><p>No fundus abnormalities are present.</p></div><div id="ccfdn.Facial_Features"><h4>Facial Features</h4><p>Dysmorphic facial features become apparent in late childhood and are particularly evident in adult males. They include a prominent midface with a well-developed nose, thickening of the perioral tissues, forwardly directed anterior dentition, and micrognathia [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>].</p></div><div id="ccfdn.Nervous_System"><h4>Nervous System</h4><p><b>Hypomyelinating peripheral neuropathy</b> is symmetric and distally accentuated, with predominantly motor involvement progressing to severe disability by the third decade of life. In a study of 28 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children ages four months to 16 years, <a class="bk_pop" href="#ccfdn.REF.kalaydjieva.2005.65">Kalaydjieva et al [2005]</a> observed an invariable delay in early motor development, with all starting to walk between ages two and three years, often with an unsteady gait. Clinical signs of lower-limb motor peripheral neuropathy (diminished or absent tendon reflexes, distal lower-limb weakness, and foot deformities) become apparent after age four years, and are soon followed by involvement of the upper limbs [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>, <a class="bk_pop" href="#ccfdn.REF.kalaydjieva.2005.65">Kalaydjieva et al 2005</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</p><p>As muscle weakness progresses, spine deformities may also develop and lead to reduction in respiratory capacity [<a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>].</p><p>Sensory abnormalities (numbness) in the lower limbs develop in persons older than age ten years.</p><p>Nerve conduction velocity is normal in infancy at the onset of myelination and subsequently (age &#x0003e;18 months) begins to decline, stabilizing at approximately 20 m/s at around age four to ten years [<a class="bk_pop" href="#ccfdn.REF.kalaydjieva.2005.65">Kalaydjieva et al 2005</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. Distal motor latencies are increased.</p><p>Sensory nerve action potentials are of normal amplitude, suggesting a relatively uniform degree of slowing of nerve conduction across nerve fibers, consistent with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hypomyelination. Sensory and motor nerves show reduction of amplitudes with disease progression, and some (<i>n. suralis</i>) can become unobtainable after age ten years, indicating secondary axonal loss [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</p><p>In distal muscles of the upper and lower extremities, neurogenic changes compatible with the underlying neuropathy are seen in all tested patients [<a class="bk_pop" href="#ccfdn.REF.tournev.1999b.165">Tournev et al 1999b</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. Electromyography, performed in six patients with proximal weakness during the rhabdomyolisis weakness episodes, showed myogenic changes in proximal muscles that were not found after recovery [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</p><p>Neuropathologic studies of sural nerve biopsies provide evidence of primary hypomyelination in the absence of morphologic abnormalities in the Schwann cell or axon [<a class="bk_pop" href="#ccfdn.REF.tournev.1999b.165">Tournev et al 1999b</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>].</p><p><b>Central nervous system</b> manifestations vary in localization and severity and occur in different combinations. In addition to the delayed motor milestones (attributed partly to the peripheral neuropathy), early intellectual development is slow, with most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children starting to talk around age three years [<a class="bk_pop" href="#ccfdn.REF.tournev.1999b.165">Tournev et al 1999b</a>, <a class="bk_pop" href="#ccfdn.REF.chamova.2015.639539">Chamova et al 2015</a>].</p><p>Formal assessment of cognitive ability reveals variable results, the interpretation of which should take into account the visual impairment, poor educational status, and language barriers (i.e., cognitive testing performed in a language other than the patient&#x02019;s mother tongue). According to the available test results, around 10% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have normal or borderline cognitive performance, and the rest have mild non-progressive intellectual deficit. Verbal memory, executive functions, and language skills are similarly affected [<a class="bk_pop" href="#ccfdn.REF.chamova.2015.639539">Chamova et al 2015</a>].</p><p>Cerebellar involvement of variable severity with ataxia, nystagmus, intention tremor, and dysmetria is common [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>, <a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>, <a class="bk_pop" href="#ccfdn.REF.lassuthova.2014.46">Lassuthova et al 2014</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>, <a class="bk_pop" href="#ccfdn.REF.chamova.2015.639539">Chamova et al 2015</a>]. Ataxia scores remain stable or improve slightly during the course of the disease [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</p><p>Pyramidal signs without spasticity and extrapyramidal hyperkinesis are observed in some [<a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>, <a class="bk_pop" href="#ccfdn.REF.chamova.2012">Chamova 2012</a>, <a class="bk_pop" href="#ccfdn.REF.chamova.2015.639539">Chamova et al 2015</a>].</p><p>Magnetic resonance imaging (MRI) findings of the brain and spinal cord vary.</p><ul><li class="half_rhythm"><div>The original study identified abnormalities in 16/17 persons [<a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>]. Diffuse cerebral and spinal cord atrophy and periventricular white matter changes, the most common findings, are more pronounced in older individuals. Brain MRI in four <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, age five months to 15 years, revealed abnormalities in three, including myelin immaturity and cerebral, cerebellar, and cervical spine hypotrophy [<a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>].</div></li><li class="half_rhythm"><div>In another study [<a class="bk_pop" href="#ccfdn.REF.kalaydjieva.2005.65">Kalaydjieva et al 2005</a>], standard MRI failed to detect any abnormalities; however, diffusion tensor MRI results suggested axonal loss in the vermis and medulla oblongata.</div></li><li class="half_rhythm"><div>A follow-up study of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> boy over a seven-year period found multifocal white matter hyperintensity on T<sub>2</sub>-weighted imaging, suggesting a progressive mild demyelinating brain process [<a class="bk_pop" href="#ccfdn.REF.cordelli.2010.343">Cordelli et al 2010</a>].</div></li><li class="half_rhythm"><div>In 19/20 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, ages four to 47 years [<a class="bk_pop" href="#ccfdn.REF.chamova.2012">Chamova 2012</a>, <a class="bk_pop" href="#ccfdn.REF.chamova.2015.639539">Chamova et al 2015</a>] brain MRI identified abnormalities including cerebral atrophy with enlargement of the lateral ventricles, hyperintense lesions in periventricular white matter and brain stem (varying from small single to multiple diffuse), and occasionally thin corpus callosum and cerebellar atrophy. Hyperintensities were located predominantly in frontal and parietooccipital periventricular white matter.</div></li><li class="half_rhythm"><div>In 7/16 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, brain MRI showed nonspecific changes, including accentuated ventricles and white matter hyperintense periventricular lesions [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</div></li></ul></div><div id="ccfdn.Other"><h4>Other</h4><p><b>Growth.</b> Intrauterine growth restriction is suggested by a study of 22 infants with CCFDN, born at term with significantly lower weight and length than in the general population [<a class="bk_pop" href="#ccfdn.REF.chamova.2012">Chamova 2012</a>]:</p><ul><li class="half_rhythm"><div><b>Males.</b> Birth weight 3.22&#x000b1;0.48 kg (reference value 3.9&#x000b1;0.5 kg); length 47.88&#x000b1;3.91cm (reference 53.1&#x000b1;2.1 cm)</div></li><li class="half_rhythm"><div><b>Females.</b> Birth weight 3.06&#x000b1;0.53 kg (reference 3.8&#x000b1;0.6 kg); length 46.75&#x000b1;4.19 cm (reference 52.5&#x000b1;2.1 cm)</div></li></ul><p>Affected aduIts are of small stature and most are also of subnormal weight [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>]:</p><ul><li class="half_rhythm"><div><b>Adult males.</b> 149.2&#x000b1;5 cm and 47&#x000b1;7.2 kg (reference values: 173&#x000b1;6.8 cm and 73.9&#x000b1;10.4 kg)</div></li><li class="half_rhythm"><div><b>Adult females.</b> 142.4&#x000b1;8.2 cm and 45.8&#x000b1;7.6 kg (reference values: 160.3&#x000b1;6.4 cm and 63&#x000b1;10.7 kg)</div></li></ul><p><b>Skeletal deformities,</b> especially of the feet and hands, develop in the course of the disease as a result of the peripheral neuropathy, and are present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> adults.</p><p><b>Endocrine system.</b> Growth hormone levels in CCFDN are in the low-normal range, with a pronounced rise after insulin-induced hypoglycemia suggesting mild regulatory deficiency [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>].</p><p>Sexual development appears unimpaired, with normal secondary characteristics after puberty and normal menarche. However, most adult females report irregular menstrual cycles and early secondary amenorrhea at ages 25-35 years.</p><p>Adults of both sexes show evidence of hypogonadotropic hypogonadism, with low testosterone and subnormal FSH levels in males and low estradiol and subnormal LH levels in females [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>]. Subnormal sex hormone levels were rarely observed in a recently reported 16 patients [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. The effect of these deficits on fertility is difficult to assess, as very few persons with CCFDN enter sexual relationships.</p><p><b>Bone mineral density</b> is decreased, possibly as the compound result of the endocrine involvement and the low physical activity due to the peripheral neuropathy [<a class="bk_pop" href="#ccfdn.REF.tournev.1999a.742">Tournev et al 1999a</a>, <a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>].</p><p><b>Parainfectious rhabdomyolysis,</b> a potentially life-threatening complication that leads to acute kidney failure, may in fact be an integral part of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Rhabdomyolysis refers to disintegration of striated muscles and the release of intracellular content into the extracellular compartment, presenting clinically as profound muscle weakness, myoglobinuria, and excessively elevated serum concentration of creatine kinase. Rhabdomyolysis in CCFDN usually develops after febrile illness (mostly viral infections) and is characterized by acute severe proximal weakness and myalgia [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. Proximal muscle weakness is not otherwise typical for CCFDN [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. The episodes are usually recurrent, acute, and dramatic, but resolve spontaneously with none of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals progressing to acute renal failure [<a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>, <a class="bk_pop" href="#ccfdn.REF.mastroyianni.2007.747">Mastroyianni et al 2007</a>, <a class="bk_pop" href="#ccfdn.REF.lassuthova.2014.46">Lassuthova et al 2014</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. Recovery of muscle function may take up to one year and such episodes can lead to deterioration in the clinical course of the peripheral neuropathy.</p><p>Muscle biopsies have shown mild myopathic features with scattered necrotic fibers, normal histochemical reactions for myophosphorylase and phosphofructokinase, and no evidence of mitochondrial pathology [<a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>].</p></div></div><div id="ccfdn.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The CCFDN <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is consistent, with little variation observed among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, all <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the ancestral <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figccfdnTselectedctdp1pathogenicvarian" rid-ob="figobccfdnTselectedctdp1pathogenicvarian">c.863+389C&#x0003e;T</a> in <i>CTDP1</i>.</p></div><div id="ccfdn.Nomenclature"><h3>Nomenclature</h3><p>Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) was also referred to as &#x02018;Marinesco-Sj&#x000f6;gren syndrome with rhabdomyolysis&#x02019; [<a class="bk_pop" href="#ccfdn.REF.m_llerfelber.1998.97">M&#x000fc;ller-Felber et al 1998</a>] until it was demonstrated that the individuals described in that study had CCFDN [<a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>].</p></div><div id="ccfdn.Prevalence"><h3>Prevalence</h3><p>Proper figures on the prevalence of CCFDN are not available. The total number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals diagnosed to date is approximately 170, all of Roma/Gypsy ethnicity.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for the <a class="figpopup" href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figccfdnTselectedctdp1pathogenicvarian" rid-ob="figobccfdnTselectedctdp1pathogenicvarian">c.863+389C&#x0003e;T</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is approximately 7% among the Rudari (the Gypsy group most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by the disorder) and approximately 1.4% in the general Roma/Gypsy population [<a class="bk_pop" href="#ccfdn.REF.morar.2004.596">Morar et al 2004</a>].</p><p>No <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals or carriers in other ethnic groups have been identified to date.</p></div></div><div id="ccfdn.Genetically_Related_Allelic_Disord"><h2 id="_ccfdn_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>CTDP1</i>.</p></div><div id="ccfdn.Differential_Diagnosis"><h2 id="_ccfdn_Differential_Diagnosis_">Differential Diagnosis</h2><p>In early infancy, when bilateral <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> cataracts are the only manifestation, the diagnosis of congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) is made highly probable by the detection of accompanying ophthalmologic abnormalities, such as microcornea and microphthalmia.</p><p>The differential diagnosis with other conditions presenting in the first year of life with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> cataracts, microcornea, and microphthalmia will be helped by the delayed developmental milestones in children with CCFDN and subsequent signs of peripheral neuropathy.</p><p><b>Galactokinase deficiency</b> (OMIM <a href="http://omim.org/entry/230200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">230200</a>), an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inborn error of galactose metabolism, is the main differential diagnosis of CCFDN in infants of Roma/Gypsy ancestry; in this ethnic group, it is caused by the p.Pro28Thr <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in <i>GK1</i> (<i>GALK1</i>) [<a class="bk_pop" href="#ccfdn.REF.kalaydjieva.1999.1299">Kalaydjieva et al 1999</a>].</p><p>CCFDN also shares findings with Marinesco-Sj&#x000f6;gren syndrome (MSS) and the <i>GBA2</i>-related Marinesco-Sj&#x000f6;gren syndrome-like disorder.</p><p><a href="/books/n/gene/mss/"><b>Marinesco-Sj&#x000f6;gren syndrome</b></a>
<b>(MSS)</b> is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder characterized by cerebellar ataxia with cerebellar atrophy, early-onset (not necessarily <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>) cataracts, myopathy, muscle weakness, and hypotonia. Additional features may include psychomotor delay, hypergonadotropic hypogonadism, short stature, and various skeletal abnormalities. Children with MSS usually present with muscular hypotonia in early infancy; distal and proximal muscular weakness is noticed during the first decade of life. Later, cerebellar findings of truncal ataxia, dysdiadochokinesis, and dysarthria become apparent. Motor function worsens progressively for some years, then stabilizes at an unpredictable age and degree of severity. Cataracts can develop rapidly and typically require lens extraction in the first decade of life. Diagnosis is based on clinical findings and/or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants of <i>SIL1</i> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>The clinical investigations providing the best distinction between CCFDN and MSS are ophthalmologic (cataracts in both disorders but extensive involvement of the anterior eye segment in CCFDN), neurophysiologic (reduced nerve conduction velocity in CCFDN), and neuroimaging (cerebellar atrophy in MSS). Electron-microscopic ultrastructural changes on muscle biopsy are thought to be specific to MSS.</p><p><b><i>GBA2-</i>related Marinesco-Sj&#x000f6;gren syndrome-like disorder</b> (OMIM <a href="http://omim.org/entry/614409" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614409</a>) is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> condition characterized by progressive cerebellar ataxia developing in early childhood accompanied by lower-limb spasticity as well as an axonal peripheral neuropathy resulting in weakness, muscle wasting, and foot deformities. Early psychomotor development is normal; however, mild progressive cognitive decline accompanies the other progressive central nervous system findings. Bilateral cataracts are observed later in the disease course [<a class="bk_pop" href="#ccfdn.REF.martin.2013.238">Martin et al 2013</a>, <a class="bk_pop" href="#ccfdn.REF.haugarvoll.2017.e0169309">Haugarvoll et al 2017</a>].</p><p>See <a href="http://omim.org/phenotypicSeries/PS309800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Microphthalmia, syndromic: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p><p>See <a href="http://omim.org/phenotypicSeries/PS116200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cataract: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="ccfdn.Management"><h2 id="_ccfdn_Management_">Management</h2><div id="ccfdn.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> cataracts, facial dysmorphism, and neuropathy (CCFDN) and to address the most disabling manifestations, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Visual impairment (ophthalmologic examination)</div></li><li class="half_rhythm"><div>Peripheral neuropathy and ensuing physical handicap (neurologic and orthopedic examinations, measurements of nerve conduction velocity)</div></li><li class="half_rhythm"><div>Endocrinologic evaluation, related to growth delay, fertility problems, and osteopenia</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ccfdn.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The treatment of cataracts is surgical. The surgical removal of cataracts may be complicated by the micropupils and fibrotic pupillary margins necessitating alternative mechanical methods of dilatation [<a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>].</p><p>Patients need close follow up because of unusually exaggerated postoperative inflammatory reactions and strong unspecific foreign-body reaction to contact lenses and intraocular lenses (intraocular lenses are generally better tolerated) [<a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>].</p><p>The management of the peripheral neuropathy includes rehabilitation and corrective surgery for the secondary bone deformities.</p><p>Hormone replacement therapy may be considered in young females with secondary amenorrhea and increased risk of osteoporosis. Regular rehabilitation can prevent or postpone osteoporosis.</p><p>Growth hormone levels in CCFDN are in low normal range and somatotropin hormone substitution is not expected to have considerable effect.</p></div><div id="ccfdn.Prevention_of_Secondary_Complicati"><h3>Prevention of Secondary Complications</h3><p>Individuals with CCFDN are prone to develop severe and potentially life-threatening complications related to anesthesia, such as pulmonary edema, inspiratory stridor, malignant hyperthermia, and epileptic seizures [<a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>] and thus need close monitoring and possibly intensive postoperative care.</p><p>Affected individuals and care providers need to be aware of rhabdomyolysis as a potential complication following viral infections, and seek medical attention with the first recognizable symptoms. Oral corticosteroid treatment for two to three weeks can result in a full recovery within two to six months [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. The long-term outcome depends on the recurrence of rhabdomyolysis episodes [<a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>].</p></div><div id="ccfdn.Surveillance"><h3>Surveillance</h3><p>Annual examinations to monitor for possible ophthalmologic, neurologic, and endocrine complications are warranted.</p></div><div id="ccfdn.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>General anesthesia in patients with CCFDN may cause complications such as pulmonary edema, inspiratory stridor, malignant hyperthermia, and epileptic seizures [<a class="bk_pop" href="#ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck et al 2004</a>]. Although such complications have not been unequivocally documented, <a class="bk_pop" href="#ccfdn.REF.masters.2017.178">Masters et al [2017]</a> recommend cautious use of general anesthesia until more information on related risks is available.</p><p>Prolonged exercise was reported to provoke myalgia in one patient with CCFDN [<a class="bk_pop" href="#ccfdn.REF.merlini.2002.231">Merlini et al 2002</a>].</p></div><div id="ccfdn.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p><ul><li class="half_rhythm"><div>If the <i>CTDP1</i> pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk sibs.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known careful monitoring of at-risk sibs for the early disease manifestations (ocular, delayed motor milestones, early signs of peripheral neuropathy) will ensure timely diagnosis of those <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p>See <a href="#ccfdn.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ccfdn.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Experience is very limited, as only three females with CCFDN are known to have given birth [<a class="bk_pop" href="#ccfdn.REF.tournev.2001.210">Tournev et al 2001</a>, <a class="bk_pop" href="#ccfdn.REF.walter.2014.1337">Walter et al 2014</a>]. The pregnancies are reported as uneventful and were carried to term. Normal pregnancy and delivery have also been reported by mothers of children with CCFDN.</p></div><div id="ccfdn.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="ccfdn.Genetic_Counseling"><h2 id="_ccfdn_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ccfdn.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Congenital cataracts, facial dysmorphism, and neuropathy (CCFDN) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ccfdn.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>CTDP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with CCFDN are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CTDP1</i>.</div></li><li class="half_rhythm"><div>However, if the reproductive partner of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (which is more likely in closely knit endogamous communities with a high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a>; see <a href="#ccfdn.Related_Genetic_Counseling_Issues">Related Genetic Counseling Issues</a>, Family planning), offspring may be affected.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>CTDP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ccfdn.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>CTDP1</i> pathogenic variants in the family.</p><p>Because of the endogamous nature of Roma communities and the increased frequency of <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> marriages, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> should be considered for the extended families of both parents and future reproductive partners of individuals already determined to be carriers.</p></div><div id="ccfdn.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ccfdn.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>Carrier testing and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> should be offered to relatives, especially in view of the endogamous nature of many Roma/Gypsy communities. Even though CCFDN is a very rare disorder in the general population, the high <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> rates in specific communities translate to an increased probability of couples at high risk having a child with CCFDN.</div></li><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ccfdn.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CTDP1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for CCFDN are possible.</p></div></div><div id="ccfdn.Resources"><h2 id="_ccfdn_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Eye Institute</b></div><div>31 Center Drive</div><div>MSC 2510</div><div>Bethesda MD 20892-2510</div><div><a href="https://www.nei.nih.gov/health/cataract/cataract_facts" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Facts About Cataract</a></div></li></ul></div><div id="ccfdn.Molecular_Genetics"><h2 id="_ccfdn_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ccfdn.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Congenital Cataracts, Facial Dysmorphism, and Neuropathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25565/table/ccfdn.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccfdn.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ccfdn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ccfdn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ccfdn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ccfdn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ccfdn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ccfdn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ccfdn.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/9150" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CTDP1</i></a></td><td headers="hd_b_ccfdn.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=9150" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">18q23</a></td><td headers="hd_b_ccfdn.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9Y5B0" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RNA polymerase II subunit A C-terminal domain phosphatase</a></td><td headers="hd_b_ccfdn.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.molgen.ua.ac.be/CMTMutations/Mutations/Contexts.cfm?ID=30" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IPN Mutations, CTDP1</a><br /><a href="http://databases.lovd.nl/shared/genes/CTDP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CTDP1 - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_ccfdn.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CTDP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CTDP1</a></td><td headers="hd_b_ccfdn.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CTDP1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CTDP1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ccfdn.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ccfdn.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Congenital Cataracts, Facial Dysmorphism, and Neuropathy (<a href="/omim/604168,604927" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25565/table/ccfdn.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccfdn.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604168" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604168</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY; CCFDN</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604927" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604927</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C-TERMINAL DOMAIN OF RNA POLYMERASE II SUBUNIT A, PHOSPHATASE OF, SUBUNIT 1; CTDP1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>CTDP1</i> spans approximately 75 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> generates two <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>: isoform a (12 exons) is a 3,775-nt long transcript; isoform b (11 exons) is 3612 nt long. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK25565/#ccfdn.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The founder CCFDN-causing variant, <a class="figpopup" href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figccfdnTselectedctdp1pathogenicvarian" rid-ob="figobccfdnTselectedctdp1pathogenicvarian">c.863+389C&#x0003e;T</a> (IVS6 + 389C&#x0003e;T), triggers an unusual mechanism of aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#ccfdn.REF.varon.2003.185">Varon et al 2003</a>]. It creates a canonical donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, which activates an upstream cryptic acceptor site and triggers a rare mechanism of aberrant splicing. The cryptic acceptor site is utilized together with the regular <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 6 donor site to splice out an upstream part of the intron, while the newly created donor site together with the regular intron 6 acceptor site serve for the splicing of a downstream part of the intron. An intermediate Alu sequence of 95 nucleotides is inserted into the processed <i>CTDP1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>, resulting in a premature termination signal 17 codons downstream of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6.</p><div id="ccfdn.T.selected_ctdp1_pathogenic_varian" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>CTDP1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccfdn.T.selected_ctdp1_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ccfdn.T.selected_ctdp1_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_ccfdn.T.selected_ctdp1_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ccfdn.T.selected_ctdp1_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ccfdn.T.selected_ctdp1_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.863+389C&#x0003e;T<br />(IVS6+389C&#x0003e;T)</td><td headers="hd_h_ccfdn.T.selected_ctdp1_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_ccfdn.T.selected_ctdp1_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_004715.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004715<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/67188445" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004706<wbr style="display:inline-block"></wbr>​.3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ccfdn.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The carboxy-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> phosphatase 1 (CTDP1), also known as <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> IIF-associating CTD phosphatase 1 (FCP1), is a widely expressed nuclear protein of 961 amino acids, with a catalytic N-terminal part, a phospho-protein-binding BRCT domain common to cell cycle check-point proteins and involved in protein-protein interactions, and a C-terminal nuclear localization signal [<a class="bk_pop" href="#ccfdn.REF.archambault.1997.14300">Archambault et al 1997</a>, <a class="bk_pop" href="#ccfdn.REF.cho.1999.1540">Cho et al 1999</a>, <a class="bk_pop" href="#ccfdn.REF.kobor.1999.55">Kobor et al 1999</a>]. CTDP1 is involved in the regulation of eukaryotic transcription, its main function being the regulation of the phosphorylation level of the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNAPII). The CTD serves as the platform for the recruitment, assembly, and interaction of multimeric protein complexes involved in the different stages of transcription and in the post-transcriptional modifications of the nascent <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> [<a class="bk_pop" href="#ccfdn.REF.maniatis.2002.499">Maniatis &#x00026; Reed 2002</a>]. The coupling and coordination of these processes is controlled by the changing level and pattern of phosphorylation of the serine 2 and 5 residues in the CTD, a &#x02018;CTD code&#x02019; that specifies the position of RNAPII in a transcription cycle [<a class="bk_pop" href="#ccfdn.REF.maniatis.2002.499">Maniatis &#x00026; Reed 2002</a>]. In vitro experiments have implicated CTDP1 in virtually all stages of the transcription cycle and multiple other processes regulating gene expression, in addition to the RNAPII recycling during transcription, such as mobilization of stored RNAPII sequestered in depots in the phosphorylated form [<a class="bk_pop" href="#ccfdn.REF.palancade.2001.6359">Palancade et al 2001</a>], the recruitment of the <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> machinery [<a class="bk_pop" href="#ccfdn.REF.licciardo.2003.999">Licciardo et al 2003</a>], and chromatin remodeling through histone <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> [<a class="bk_pop" href="#ccfdn.REF.amente.2005.683">Amente et al 2005</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> CCFDN is caused by reduced level/function of the CTDP1 protein (see <b>Normal gene product</b>). Some normal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> (15%-35%) occurs in CCFDN cells, therefore, <a class="figpopup" href="/books/NBK25565/table/ccfdn.T.selected_ctdp1_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figccfdnTselectedctdp1pathogenicvarian" rid-ob="figobccfdnTselectedctdp1pathogenicvarian">c.863+389C&#x0003e;T</a> results in a partial deficiency of the carboxy-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> phosphatase 1 [<a class="bk_pop" href="#ccfdn.REF.varon.2003.185">Varon et al 2003</a>, <a class="bk_pop" href="#ccfdn.REF.kalaydjieva.2016">Kalaydjieva et al 2016</a>].</p></div><div id="ccfdn.References"><h2 id="_ccfdn_References_">References</h2><div id="ccfdn.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.amente.2005.683">Amente S, Naplitano G, Licciardo P, Monti M, Pucci P, Lania L, Majello B. Identification of proteins interacting with the RNAPII FCP1 phosphatase: FCP1 forms a complex with arginine methyltransferase PRMT5 and it is a substrate for PRMT5-mediated methylation. <span><span class="ref-journal">FEBS Lett. </span>2005;<span class="ref-vol">579</span>:683–9.</span> [<a href="/pubmed/15670829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15670829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.archambault.1997.14300">Archambault J, Chambers RD, Kobor MS, Ho Y, Cartier M, Bolotin D, Andrews B, Kane CM, Greenblatt J. An essential component of a C-terminal domain phosphatase that interacts with transcription factor IIF in S. cerevisiae. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1997;<span class="ref-vol">94</span>:14300–5.</span> [<a href="/pmc/articles/PMC24951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC24951</span></a>] [<a href="/pubmed/9405607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9405607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.chamova.2012">Chamova T. Investigation of the cognitive impairment of patients with neuromuscular disorders. Sofia, Bulgaria: Sofia Medical University; 2012.</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.chamova.2015.639539">Chamova T, Zlatareva D, Raycheva M, Bichev S, Kalaydjieva L, Tournev I. Cognitive impairment and brain imaging characteristics of patients with congenital cataracts, facial dysmorphism, neuropathy syndrome. <span><span class="ref-journal">Behav Neurol. </span>2015;<span class="ref-vol">2015</span>:639539.</span> [<a href="/pmc/articles/PMC4427823/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4427823</span></a>] [<a href="/pubmed/26060356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26060356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.cho.1999.1540">Cho H, Kim TK, Mancebo H, Lane WS, Flores O, Reinberg D. A protein phosphatase functions to recycle RNA polymerase II. <span><span class="ref-journal">Genes &#x00026; Dev. </span>1999;<span class="ref-vol">13</span>:1540–52.</span> [<a href="/pmc/articles/PMC316795/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC316795</span></a>] [<a href="/pubmed/10385623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10385623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.cordelli.2010.343">Cordelli DM, Garone C, Marchiani V, Lodi R, Tonon C, Ferrari S, Seri M, Franzoni E. Progressive cerebral white matter involvement in a patient with Congenital Cataracts Facial Dysmorphisms Neuropathy (CCFDN). <span><span class="ref-journal">Neuromuscul Disord. </span>2010;<span class="ref-vol">20</span>:343–5.</span> [<a href="/pubmed/20350809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20350809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.haugarvoll.2017.e0169309">Haugarvoll K, Johansson S, Rodriguez CE, Boman H, Haukanes BI, Bruland O, Roque F, Jonassen I, Blomqvist M, Telstad W, M&#x000e5;nsson JE, Knappskog PM, Bindoff LA. GBA2 Mutations Cause a Marinesco-Sj&#x000f6;gren-Like Syndrome: Genetic and Biochemical Studies. <span><span class="ref-journal">PLoS One. </span>2017;<span class="ref-vol">12</span>:e0169309.</span> [<a href="/pmc/articles/PMC5215700/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5215700</span></a>] [<a href="/pubmed/28052128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28052128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.kalaydjieva.2005.65">Kalaydjieva L, Lochm&#x000fc;ller H, Tournev I, Baas F, Beres J, Colomer J, Guergueltcheva V, Herrmann R, Karcagi V, King R, Miyata T, M&#x000fc;llner-Eidenb&#x000f6;ck A, Okuda T, Milic Rasic V, Santos M, Talim B, Vilchez J, Walter M, Urtizberea A, Merlini L. 125th ENMC International Workshop: Neuromuscular Disorders in the Roma (Gypsy) population, 23-25 April 2004, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:65–71.</span> [<a href="/pubmed/15639123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15639123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.kalaydjieva.1999.1299">Kalaydjieva L, Perez-Lezaun A, Angelicheva D, Onengut S, Dye D, Bosshard N, Jordanova A, Savov A, Yanakiev P, Kremensky I, Radeva B, Hallmayer J, Markov A, Nedkova V, Tournev I, Aneva L, Gitzelmann R. A founder mutation in the GK1 gene is responsible for galactokinase deficiency in Gypsies. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">65</span>:1299–307.</span> [<a href="/pmc/articles/PMC1288282/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288282</span></a>] [<a href="/pubmed/10521295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10521295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.kalaydjieva.2016">Kalaydjieva L, Chamova T, Gooding R. Carboxy-terminal domain phosphatase 1: congenital cataracts-facial dysmorphism-neuropathy syndrome. In: Erickson RP, Wynshaw-Boris AJ, eds: <em>Epstein's Inborn Errors of Development.The Molecular Basis of Clinical Disorders of Morphogenesis.</em> 3 ed. Oxford University Press. 2016:1001-5.</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.kobor.1999.55">Kobor MS, Archambault J, Lester W, Holstege FC, Gieladi O, Jausma DB, Jennings EG, Kouyoumdjan F, Davidson AR, Young RA, Greenblatt J. An unusual eukaryotic protein phosphatase required for transcription by RNA polymerase II and CTD dephosphorylation in S. cerevisiae. <span><span class="ref-journal">Mol Cell. </span>1999;<span class="ref-vol">4</span>:55–62.</span> [<a href="/pubmed/10445027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10445027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.lassuthova.2014.46">Lassuthova P, Si&#x00161;kov&#x000e1; D, Haberlov&#x000e1; J, Sakmaryov&#x000e1; I, Filou&#x00161; A, Seeman P. Congenital cataract, facial dysmorphism and demyelinating neuropathy (CCFDN) in 10 Czech Gypsy children--frequent and underestimated cause of disability among Czech Gypsies. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014;<span class="ref-vol">9</span>:46.</span> [<a href="/pmc/articles/PMC3976362/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3976362</span></a>] [<a href="/pubmed/24690360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24690360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.licciardo.2003.999">Licciardo P, Amente S, Ruggiero L, Monti M, Pucci P, Lania L, Majello B. The FCP1 phosphatase interacts with RNA polymerase II and with MEP50 a component of the methylosome complex involved in the assembly of snRNP. <span><span class="ref-journal">Nucl Acids Res. </span>2003;<span class="ref-vol">31</span>:999–1005.</span> [<a href="/pmc/articles/PMC149217/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC149217</span></a>] [<a href="/pubmed/12560496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12560496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.maniatis.2002.499">Maniatis T, Reed R. An extensive network of coupling among gene expression machines. <span><span class="ref-journal">Nature. </span>2002;<span class="ref-vol">416</span>:499–506.</span> [<a href="/pubmed/11932736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11932736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.martin.2013.238">Martin E, Sch&#x000fc;le R, Smets K, Rastetter A, Boukhris A, Loureiro JL, Gonzalez MA, Mundwiller E, Deconinck T, Wessner M, Jornea L, Oteyza AC, Durr A, Martin JJ, Sch&#x000f6;ls L, Mhiri C, Lamari F, Z&#x000fc;chner S, De Jonghe P, Kabashi E, Brice A, Stevanin G. Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:238–44.</span> [<a href="/pmc/articles/PMC3567271/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3567271</span></a>] [<a href="/pubmed/23332916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23332916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.masters.2017.178">Masters OW, Bergmans E, Thies KC. Anaesthesia and orphan disease: A child with Congenital Cataract Facial Dysmorphism neuropathy (CCFDN) syndrome: a case report. <span><span class="ref-journal">Eur J Anaesthesiol. </span>2017;<span class="ref-vol">34</span>:178–80.</span> [<a href="/pubmed/28141735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28141735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.mastroyianni.2007.747">Mastroyianni SD, Garoufi A, Voudris K, Skardoutsou A, Gooding R, Kalaydjieva L. Congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome: a rare cause of parainfectious rhabdomyolysis. <span><span class="ref-journal">Eur J Pediatr. </span>2007;<span class="ref-vol">166</span>:747–9.</span> [<a href="/pubmed/17195938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17195938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.merlini.2002.231">Merlini L, Gooding R, Lochmueller H, Walter MC, Angelicheva D, Talim B, Hallmayer J, Kalaydjieva L. Genetic identity of Marinesco-Sj&#x000f6;gren/ myoglobinuria and CCFDN syndromes. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:231–6.</span> [<a href="/pubmed/11805249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11805249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.morar.2004.596">Morar B, Gresham D, Angelicheva D, Tournev I, Gooding R, Guergueltcheva V, Schmidt C, Abicht A, Lochm&#x000fc;ller H, Tordai A, Kalmar L, Nagy M, Karcagi V, Jeanpierre M, Herczegfalvi A, de Pablo R, Kucinskas V, Kalaydjieva L. Mutation history of the Roma/Gypsies. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">75</span>:596–609.</span> [<a href="/pmc/articles/PMC1182047/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182047</span></a>] [<a href="/pubmed/15322984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15322984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.m_llerfelber.1998.97">M&#x000fc;ller-Felber W, Zafiriou D, Scheck R, P&#x000e4;tzke I, Toepfer M, Pongratz DE, Walther U. Marinesco-Sj&#x000f6;gren syndrome with rhabdomyolysis. A new subtype of the disease. <span><span class="ref-journal">Neuropediatrics. </span>1998;<span class="ref-vol">29</span>:97–101.</span> [<a href="/pubmed/9638664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9638664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.m_llnereidenb_ck.2004.1415">M&#x000fc;llner-Eidenb&#x000f6;ck A, Moser E, Klebermass N, Amon M, Mernert G, Walther M, Lochmueller H, Kalaydjieva L. Ocular features of the CCFDN syndrome (congenital cataracts facial dysmorphism neuropathy). <span><span class="ref-journal">Ophthalmology. </span>2004;<span class="ref-vol">111</span>:1415–23.</span> [<a href="/pubmed/15234148" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15234148</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.palancade.2001.6359">Palancade B, Dubois MF, Dahmus ME, Bensaude O. Transcription-independent RNA polymerase II dephosphorylation by the FCP1 carboxy-terminal domain phosphatase in Xenopus laevis early embryos. <span><span class="ref-journal">Mol Cell Biol. </span>2001;<span class="ref-vol">21</span>:6359–68.</span> [<a href="/pmc/articles/PMC99784/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC99784</span></a>] [<a href="/pubmed/11533226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11533226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.tournev.1999a.742">Tournev I, Kalaydjieva L, Youl B, Ishpekova B, Guerguelcheva V, Kamenov O, Katzarova M, Kamenov Z, Raicheva-Ternzieva M, King RHM, Petkov R, Shmarov A, Dimitrova G, Popova N, Uzunova M, Milanov S, Petrova J, Petkov Y, Kolarov G, Anev L, Radeva O, Thomas PK. Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome, a novel complex genetic disease in Balkan Gypsies: clinical and electrophysiological observations. <span><span class="ref-journal">Ann Neurol. </span>1999a;<span class="ref-vol">45</span>:742–50.</span> [<a href="/pubmed/10360766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10360766</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.tournev.1999b.165">Tournev I, King RH, Workman J, Nourallah M, Muddle JR, Kalaydjieva L, Romanski K, Thomas PK. Peripheral nerve abnormalities in the congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome. <span><span class="ref-journal">Acta Neuropathol. </span>1999b;<span class="ref-vol">98</span>:165–70.</span> [<a href="/pubmed/10442556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10442556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.tournev.2001.210">Tournev I, Thomas P, Gooding R, Angelicheva D, King R, Youl B, Guerueltcheva V, Ishpekova B, Blechsmidt K, Swoboda K, Petkov R, Molnar M, Kamenov Z, Siska E, Taneva N, Borisova P, Lupu C, Raycheva M, Trifonova N, Popova A, Corches A, Litvinenko I, Merlini L, Katzarova M, Tzankov B, Popa G, Akkari A, Rosenthal A, Donzelli O, Kalaydjieva L. Congenital cataracts facial dysmorphism neuropathy (CCFDN) syndrome &#x02013; Clinical, neuropathological and genetic investigation. <span><span class="ref-journal">Acta Myologica. </span>2001;<span class="ref-vol">20</span>:210–9.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.varon.2003.185">Varon R, Gooding R, Steglich C, Marns L, Tang H, Angelicheva D, Yong KK, Ambrugger P, Reinhold A, Morar B, Baas F, Kwa M, Tournev I, Guerguelcheva V, Kremensky I, Lochm&#x000fc;ller H, M&#x000fc;llner-Eidenb&#x000f6;ck A, Merlini L, Neumann L, B&#x000fc;rger J, Walter M, Swoboda K, Thomas PK, von Moers A, Risch N, Kalaydjieva L. Partial deficiency of the C-terminal domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">35</span>:185–9.</span> [<a href="/pubmed/14517542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14517542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccfdn.REF.walter.2014.1337">Walter MC, Bernert G, Zimmermann U, M&#x000fc;llner-Eidenb&#x000f6;ck A, Moser E, Kalaydjieva L, Lochm&#x000fc;ller H, M&#x000fc;ller-Felber W. Long-term follow-up in patients with CCFDN syndrome. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">83</span>:1337–44.</span> [<a href="/pubmed/25186864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25186864</span></a>]</div></li></ul></div></div><div id="ccfdn.Chapter_Notes"><h2 id="_ccfdn_Chapter_Notes_">Chapter Notes</h2><div id="ccfdn.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>6 April 2017 (ha/bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 October 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 August 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 March 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>29 October 2009 (lk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK25565</span><span class="label">PMID: <a href="/pubmed/20301787" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301787</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pai-1-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ondine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK25565&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK25565/?report=reader">PubReader</a></li><li><a href="/books/NBK25565/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK25565" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK25565" style="display:none" title="Cite this Page"><div class="bk_tt">Kalaydjieva L, Chamova T. Congenital Cataracts, Facial Dysmorphism, and Neuropathy. 2010 Mar 2 [Updated 2017 Apr 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK25565/pdf/Bookshelf_NBK25565.pdf">PDF version of this page</a> (186K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ccfdn.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ccfdn.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ccfdn.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ccfdn.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ccfdn.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ccfdn.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ccfdn.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ccfdn.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ccfdn.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ccfdn.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ccfdn.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9150[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CTDP1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK25565+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1951516" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1951516" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1951516" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1951516" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15234148" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Ocular features of the congenital cataracts facial dysmorphism neuropathy syndrome.</a><span class="source">[Ophthalmology. 2004]</span><div class="brieflinkpop offscreen_noflow">Ocular features of the congenital cataracts facial dysmorphism neuropathy syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Müllner-Eidenböck A, Moser E, Klebermass N, Amon M, Walter MC, Lochmüller H, Gooding R, Kalaydjieva L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ophthalmology. 2004 Jul; 111(7):1415-23. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16939648" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital cataracts-facial dysmorphism-neuropathy.</a><span class="source">[Orphanet J Rare Dis. 2006]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital cataracts-facial dysmorphism-neuropathy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kalaydjieva L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2006 Aug 29; 1:32. Epub 2006 Aug 29.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301468" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301726" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Insensitivity to Pain with Anhidrosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Insensitivity to Pain with Anhidrosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Indo Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29300443" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> RAB18 Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> RAB18 Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Handley M, Sheridan E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301787" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301787" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04294275f66d18aae71f1d">Congenital Cataracts, Facial Dysmorphism, and Neuropathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Congenital Cataracts, Facial Dysmorphism, and Neuropathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:30:10-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE895F0AE04241F10000000002AA012B&amp;ncbi_session=CE895F0AE0429411_0682SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK25565%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK25565&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK25565/&amp;ncbi_pagename=Congenital Cataracts, Facial Dysmorphism, and Neuropathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE895F0AE0429411_0682SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>